According to Orchard Therapeutics 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 17.405. At the end of 2023 the company had a P/S ratio of 8.04.
Year | P/S ratio | Change |
---|---|---|
2023 | 8.04 | 287.67% |
2022 | 2.07 | -97.9% |
2021 | 98.9 | -39.55% |
2020 | 164 | -69.15% |
2019 | 530 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Organovo ONVO | 42.7 | 145.52% | ๐บ๐ธ USA |
Orchard Therapeutics
ORTX | 17.4 | 0.00% | ๐ฌ๐ง UK |
Novavax NVAX | 0.9647 | -94.46% | ๐บ๐ธ USA |
Novocure
NVCR | 3.29 | -81.12% | Jersey |